

Supplementary Table 4. Association of prioritized variant candidates with disease progression in CD and UC cohorts

Gene	rsID	Outcome	Type	OR	CI_L	CI_H	p	Beta	SE	N_Case	N_Ctrl	N_Total	N_Carrier	N_Event_Carrier	N_Noncarrier	N_Event_Noncarrier
GSG1	rs146166808	OnsetAge	IBD	12.52	0.59	264.79	0.050	2.53	1.56	60	146	206	2	2	204	58
ZNF286A	rs184773569	OnsetAge	IBD	7.39	0.30	183.92	0.180	2.00	1.64	60	146	206	1	1	205	59
FRMD4B	rs144459338	OnsetAge	IBD	7.39	0.30	183.92	0.180	2.00	1.64	60	146	206	1	1	205	59
DLL3	rs776036444	OnsetAge	IBD	0.48	0.02	10.10	0.609	-0.74	1.56	60	146	206	2	0	204	60
GSG1	rs146166808	OnsetAge	CD	5.48	0.26	117.55	0.207	1.70	1.56	43	45	88	2	2	86	41
ZNF454	rs184153007	OnsetAge	UC	1.91	0.07	48.91	0.710	0.65	1.65	17	101	118	1	0	117	17
GLYATL1	rs117190061	OnsetAge	UC	1.91	0.07	48.91	0.710	0.65	1.65	17	101	118	1	0	117	17
SALL3	rs200143215	OnsetAge	UC	1.91	0.07	48.91	0.710	0.65	1.65	17	101	118	1	0	117	17
P2RY1	rs118182811	OnsetAge	UC	1.91	0.07	48.91	0.710	0.65	1.65	17	101	118	1	0	117	17
IGLL1	rs139571703	OnsetAge	UC	0.42	0.02	7.79	0.513	-0.87	1.49	17	101	118	6	0	112	17
SLC23A2	rs141901582	Extreme	IBD	0.80	0.12	5.19	0.810	-0.23	0.96	60	146	206	5	1	201	59
SERPINA6	rs146744332	Extreme	IBD	1.03	0.15	7.17	0.973	0.03	0.99	60	146	206	4	1	202	59

Data are presented for disease progression analysis. *p* values were calculated using Firth logistic regression adjusted for sex.

OR, odds ratio; CI, 95% confidence interval (lower and upper limits); Beta, effect size (log-odds ratio); SE, standard error; N, number of individuals (case, progression group; control, non-progression group; total, combined; carrier, variant carrier; carrier_event, variant carrier with progression; non-carrier, variant non-carrier; non-carrier_event, variant non-carrier with progression); IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; rsID, reference SNP cluster ID.